IL-CG-LIFE
5.1.2023 14:01:43 CET | Business Wire | Press release
CG Life, an integrated digital marketing and public relations agency supporting life science and healthcare companies, and MC Services AG, a major European public relations and investor relations firm with a similar life sciences focus, announced today a strategic partnership between the agencies. The two companies have created an integrated service platform for biotech and pharmaceutical companies to extend their reach and access more easily to capital, talent, and business audiences on both sides of the Atlantic. Both firms will remain fully and legally independent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005125/en/
For MC Services, this partnership provides an industry-respected gateway for accessing marketing, branding, digital marketing, public relations, and advertising capabilities in the U.S. And as CG Life’s clients increasingly request global capabilities across PR, branding, paid media, and more, CG Life will be able to activate a highly experienced communications and investor relations team in Europe and in Germany, in particular—the largest European healthcare market.
“Accessing the U.S. market is vital for the European biopharma sector, and we have worked for many years to better connect our clients to the life science ecosystem in the States,” said Raimund Gabriel, Managing Partner of MC Services. “We are excited to continue that mission by establishing a strategic alliance with CG Life, a like-minded agency in the U.S. with a global view that is equally committed to quality and performance.”
“Through extensive discussion, analysis, and reflection, both agency teams recognized that we share very similar cultural values, commitment to our clients and science, and an emphasis on providing business solutions rather than just delivering services,” said CG Life Managing Partner Erik Clausen. “We couldn’t be happier that we found a partner in MC Services that has the experience, skill and mindset, and relationships to collaborate with us and our clients.”
About MC Services AG
MC Services AG is an international public relations and investor relations firm specializing in communications for the life sciences and healthcare sectors. A strong team of science, finance, media, and communication experts, with extensive industry experience, positions MC Services as a leading life sciences agency in Europe.
MC Services' long-standing clients include international public and private companies, as well as venture capitalists and investment firms. Established for many years as a link between the healthcare industry and the financial markets, MC Services provides comprehensive services in investor relations, public relations, and financial transactions. MC Services is based in Munich, Düsseldorf, Berlin, London, and Boston. www.mc-services.eu
About CG Life
Propelled by science since 2003, CG Life’s mission is to celebrate scientific discoveries and medical innovations through personal and impactful brand experiences. The team integrates smart strategies, inspirational creativity, insightful content, clever communications, and digital platforms to create and elevate leading and disruptive science and healthcare brands. CG Life supports emerging science and technology organizations through The Market Element, a CG Life Agency. Connect with CG Life on LinkedIn, Twitter, Instagram or Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005125/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom